Dr. John Cush RheumNow
7 years 4 months ago
"The Coach" is the title of my 15-minute TED-like talk at RheumNow Live. I'd like to know what you think. Check it out (for free) by registering for RheumNow Live On Demand https://t.co/1jGiIQXvua #rheumed
Dr. John Cush RheumNow
7 years 5 months ago
Study of hematuria in 86 ANCA Associated Vasculitis pts, compared half with & without hematuria after achieving remission from their glomerulonephritis. Hematuria at remission was not assoc w/ ESRD, but with relapse within 44 mos https://t.co/1ld4lOX1ih
Dr. John Cush RheumNow
7 years 5 months ago
US National Inpatient study compared 30 912 TKAs in SLE pts vs 8million non-SLE and found SLE had no greater risk for implant infection, implant revision or mortality, but did have more transfusions, longer hosp stay, more Hosp charges https://t.co/LM3dM6KSfc
A study of osteoarthritis patients, finds that pain is the primary driver for health care utilization, and that the presence of insomnia or depression augments health care use.
A total of 2976 OA patients were followed for 3 years and assessed for pain (Graded Chronic Pain Scale), insomnia (Insomnia Severity Index), and depression (Patient Health Questionnaire‐8), and health care use (from electronic health records).
In August 2018, the CMS announced that Medicare Advantage (MA) plans would be allowed to utilize step therapy for Part B drugs. The American College of Rheumatology (ACR) expressed strong concerns about this proposal. The rheumatology community received some good news in this week’s final rule from CMS, which makes changes to the original proposal and addresses several of the community’s recommendations.
Dr. John Cush RheumNow
7 years 5 months ago
A national database study of 165,748 young females suggest Oral contraceptive use was associated with an 18% (OR 0.82) reduction in anterior cruciate ligament tears. Even lower in 15–19yr olds (OR 0.37). NNT for OCP usage in 15–19 age group was six. https://t.co/If4L5Aq5XJ
Dr. John Cush RheumNow
7 years 5 months ago
Should all CTD patients have PFTs? Review suggests all should have PFTs, DLCO, HiRes Chest CT given prevalence of ILD in RA, PSS, SLE, myositis. PFTs have prognostic value in RA-ILD, esp w/ UIP, but other CTDs have less data on sensitivity/specificity https://t.co/fmG9HfHLt3
Dr. John Cush RheumNow
7 years 5 months ago
multicenter, cross-sectional study of 1526 adult Behcets patients from Egyptian rheumatology centers shows CNS, DVT, and GI tract involvement is higher in males, while the joint dz and disease activity were increased in females. https://t.co/oDDRXmBfw3
Among patients with rheumatoid arthritis (RA) who had interstitial lung disease (ILD), the pattern of ILD did influence mortality, but other pulmonary factors also contributed, a meta-analysis suggested.
A lupus registry from San Francisco County analyzed racial/ethnic differences in lupus manifestations and found significant differences in SLE manifestations among racial/ethnic groups. Researchers found that Blacks, Asians/Pacific Islanders (API), and Hispanics are more likely to develop severe manifestations following a diagnosis of SLE.
From their database, they identified 724 SLE patients, and identified specific features in different
Dr. John Cush RheumNow
7 years 5 months ago
Fibomyalgia patients who undergo Knee replacements have significantly more complications (OR 1.55), revisions (OR 1.5), mechanical loosening (OR 1.34) & infection (OR 1.33). MDs and FM pts should be made aware of increased postoperative risks. https://t.co/muFQoco9zg
Dr. John Cush RheumNow
7 years 5 months ago
Toronto Lupus clinic follow up of 267 patients followe for > 10 years finds that only (10% achieved prolonged clinical remission and 18% attained prolonged Low Dz Activity. Both groups had similar low flare rates - 0.038 & 0.065 flares/year/pt. https://t.co/iLJKW0Q7FQ
Dr. John Cush RheumNow
7 years 5 months ago
US Supreme court has rejected lawsuits against Merck & Fosamax over rare atypical femoral Fx and has directed the lower court to reconsider ruling allowing lawsuits against despite the FDA denying Mercks attempt to update the label about fracture risk https://t.co/xvJlDntuuK

